Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock

$0.69

12.25% yesterday

Nasdaq, Nov 15, 09:49 pm CET

ISIN

US23254X2018

Symbol

CYTH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock price

$0.70

-24.19 97.19% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

+0.08 13.71%

ISIN

US23254X2018

Symbol

CYTH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$17.64m
Enterprise Value	$19.52m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	17.27
P/S ratio (TTM) P/S ratio	15.61
P/B ratio (TTM) P/B ratio	negative
Revenue growth (TTM) Revenue growth	-8.52%
Revenue (TTM) Revenue	$870.00k
EBIT (operating result TTM) EBIT	$-24.68m
Cash position	$1.12m
EPS (TTM) EPS	$-0.90
P/E forward	negative
P/S forward	18.25
EV/Sales forward	20.20
Short interest	0.46%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Cyclo Therapeutics Inc - Ordinary Shares - Class A forecast:

1x Buy

33%

2x Hold

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Cyclo Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy

33%

Hold

67%

Analyst Estimates with Stock Price Targets

Financial data from Cyclo Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	0.87 0.87	8% 8% 100%
- Direct Costs	- -	- -
Gross Profit	-2.64 -2.64	0% 0% -303%
- Selling and Administrative Expenses	- -	- -
- Research and Development Expense	16 16	21% 21% 1,836%
EBITDA	- -	- -
- Depreciation and Amortization	0.01 0.01	50% 50% 1%
EBIT (Operating Income) EBIT	-25 -25	27% 27% -2,836%
Net Profit	-25 -25	28% 28% -2,851%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral

Business Wire

●

one day ago

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update. “The third quarter...

Neutral

Business Wire

●

2 months ago

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the presentation of positive preliminary data from its ongoing pivotal Phase 3 study (“TransportNP...

Neutral

PRNewsWire

●

3 months ago

Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

More Cyclo Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Head office	United States
CEO	Scott Fine
Employees	8
Founded	1990
Website	www.cyclotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now